StreetAlpha.app
Home › Stocks › SCNX

Scienture Holdings, Inc. (SCNX)

$2.76
▼ −7.69%
LAST CLOSE · NOV 17

Scienture is a pharmaceutical company that markets and develops prescription medicines for heart and nervous system diseases. It last closed at $2.76 on Nov 17, down 7.69% on the day.

AI Auto Pilots
Is SCNX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.5M
+127.4% vs a year ago
Net income
−$40.4M
−2715.9% margin
Gross margin
78.5%
$1.2M gross profit
Operating margin
−2788.5%
−$41.4M operating income
Valuation
Market cap
$4.9M
1.8M shares
P/E
–
Price to sales
3.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$4.7M
At Sep 30
Shareholder equity
$58.7M
Shares outstanding
1.8M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $9.9M$9.9MFY2021FY2022: $10.3M$10.3MFY2022FY2023: $1.4M$1.4MFY2023FY2024: $137K$137KFY2024FY2025: $432K$432KFY2025

From SCNX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated SCNX in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 117.4% upside

Based on 1 analyst who set a price target on SCNX in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $2.76.

Low $6.00Avg $6.00High $6.00
Blue marker: last close $2.76
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
Maxim GroupMaintained
Oct 23Buy$6
DateFirmActionRatingPrice target
Oct 23Maxim GroupMaintainedBuy$6
Loading…

Technical Analysis

SCNX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 12% below its 20 day and 71% below its 50 day average. It is 213% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 30), near oversold. The nearest support is the Pivot S1 at $2.66, and the nearest resistance the Pivot at $2.83.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 11.4%/day
Key levels
$18.7552 week high+579.3%
$8.63200 day average+212.7%
$7.27100 day average+163.4%
$4.7350 day average+71.4%
$3.46Swing high (Nov 4)+25.4%
$3.1020 day average+12.3%
$2.93Pivot R1+6.2%
$2.83Pivot+2.5%
$2.76Last close
$2.66Pivot S1−3.6%
$2.6452 week low−4.3%
$2.64Swing low (Oct 23)−4.3%
Indicators
RSI (14)30.35Weak, oversold below 30Neutral
MACD-0.46Above its signal lineBullish
Stochastic11.3Near the bottom of its rangeOversold
ADX (14)38.7Trending down
Williams %R-96.8Oversold below −80, overbought above −20Oversold
CCI (20)-110.2Oversold below −100, overbought above 100Oversold
Rate of change−20.0%Change over 10 sessionsBearish
ATR (14)$0.32Typical daily range, 11.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SCNX

What happened before

See how SCNX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in SCNX in the last 90 days.

Loading…

See today’s whale options flow across the market →

SCNX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼4 buying vs 9 selling
  • ▲Held by funds +3.7 pts
  • ▼Funds holding -2
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1416−12.5%
In funds' top 1000–
Held by funds117.1%113.3%+3.7 pts
New / increased2 / 24 / 5−55.6%
Reduced / sold out5 / 44 / 2+50.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SCNX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SCNX is in one of them and how their past SCNX trades turned out.

SCNX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SCNX in an article yet. Here's the latest on the wider market.

About Scienture Holdings

Scienture is a specialty pharmaceutical company based in Commack, New York. It markets and develops prescription medicines for cardiovascular and central nervous system conditions, serving patients in the United States. Its marketed products include an oral liquid form of losartan for high blood pressure and a nasal spray naloxone product for opioid overdose. The company also has a pipeline of candidate treatments for conditions such as migraine, blood clots, and pain.

Headquarters
Commack, NY